The CFTR-Associated Ligand Arrests the Trafficking of the Mutant ΔF508 CFTR Channel in the ER Contributing to Cystic Fibrosis

Overview

Journal Cell Physiol Biochem

Specialties Biochemistry
Cell Biology
Pharmacology

Date 2018 Feb 7

PMID 29402832

Citations 10

Authors

Emily Bergbower

Clement Boinot

Inna Sabirzhanova

William Guggino

Liudmila Cebotaru

Affiliations

Soon will be listed here.

Abstract

Background/aims: The CFTR-Associated Ligand (CAL), a PDZ domain containing protein with two coiled-coil domains, reduces cell surface WT CFTR through degradation in the lysosome by a well-characterized mechanism. However, CAL's regulatory effect on ΔF508 CFTR has remained almost entirely uninvestigated.

Methods: In this study, we describe a previously unknown pathway for CAL by which it regulates the membrane expression of ΔF508 CFTR through arrest of ΔF508 CFTR trafficking in the endoplasmic reticulum (ER) using a combination of cell biology, biochemistry and electrophysiology.

Results: We demonstrate that CAL is an ER localized protein that binds to ΔF508 CFTR and is degraded in the 26S proteasome. When CAL is inhibited, ΔF508 CFTR retention in the ER decreases and cell surface expression of mature functional ΔF508 CFTR is observed alongside of enhanced expression of plasma membrane scaffolding protein NHERF1. Chaperone proteins regulate this novel process, and ΔF508 CFTR binding to HSP40, HSP90, HSP70, VCP, and Aha1 changes to improve ΔF508 CFTR cell surface trafficking.

Conclusion: Our results reveal a pathway in which CAL regulates the cell surface availability and intracellular retention of ΔF508 CFTR.

Citing Articles

Identification of novel natural compounds against CFTR p.Gly628Arg pathogenic variant.

Khan M, Sakhawat A, Rehman R, Wali A, Ghani M, Akram A AMB Express. 2024; 14(1):99.

PMID: 39249658 PMC: 11383896. DOI: 10.1186/s13568-024-01762-9.

The double whammy of ER-retention and dominant-negative effects in numerous autosomal dominant diseases: significance in disease mechanisms and therapy.

Gariballa N, Mohamed F, Badawi S, Ali B J Biomed Sci. 2024; 31(1):64.

PMID: 38937821 PMC: 11210014. DOI: 10.1186/s12929-024-01054-1.

CTNNAL1 deficiency suppresses CFTR expression in HDM-induced asthma mouse model through ROCK1-CAL signaling pathway.

Wu D, Zhu J, Yang F, Li R, Liu L, Liu D Acta Biochim Biophys Sin (Shanghai). 2023; 55(10):1618-1629.

PMID: 37715489 PMC: 10579809. DOI: 10.3724/abbs.2023152.

Ubiquitin-like processing of TUG proteins as a mechanism to regulate glucose uptake and energy metabolism in fat and muscle.

Bogan J Front Endocrinol (Lausanne). 2022; 13:1019405.

PMID: 36246906 PMC: 9556833. DOI: 10.3389/fendo.2022.1019405.

Drug efficacy and toxicity prediction: an innovative application of transcriptomic data.

Xia X Cell Biol Toxicol. 2020; 36(6):591-602.

PMID: 32780246 PMC: 7661398. DOI: 10.1007/s10565-020-09552-2.

References

Cheng J, Moyer B, Milewski M, Loffing J, Ikeda M, Mickle J . A Golgi-associated PDZ domain protein modulates cystic fibrosis transmembrane regulator plasma membrane expression. J Biol Chem. 2001; 277(5):3520-9. DOI: 10.1074/jbc.M110177200. View

Farinha C, Nogueira P, Mendes F, Penque D, Amaral M . The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70. Biochem J. 2002; 366(Pt 3):797-806. PMC: 1222832. DOI: 10.1042/BJ20011717. View

Cheng J, Wang H, Guggino W . Modulation of mature cystic fibrosis transmembrane regulator protein by the PDZ domain protein CAL. J Biol Chem. 2003; 279(3):1892-8. DOI: 10.1074/jbc.M308640200. View

Cheng J, Wang H, Guggino W . Regulation of cystic fibrosis transmembrane regulator trafficking and protein expression by a Rho family small GTPase TC10. J Biol Chem. 2004; 280(5):3731-9. DOI: 10.1074/jbc.M410026200. View

Benharouga M, Sharma M, Lukacs G . CFTR folding and maturation in cells. Methods Mol Med. 2002; 70:229-43. DOI: 10.1385/1-59259-187-6:229. View

Goldstein R, Niraj A, Sanderson T, Wilson L, Rab A, Kim H . VCP/p97 AAA-ATPase does not interact with the endogenous wild-type cystic fibrosis transmembrane conductance regulator. Am J Respir Cell Mol Biol. 2007; 36(6):706-14. PMC: 1899338. DOI: 10.1165/rcmb.2006-0365OC. View

Gee H, Noh S, Tang B, Kim K, Lee M . Rescue of ΔF508-CFTR trafficking via a GRASP-dependent unconventional secretion pathway. Cell. 2011; 146(5):746-60. DOI: 10.1016/j.cell.2011.07.021. View

Pilewski J, Frizzell R . Role of CFTR in airway disease. Physiol Rev. 1999; 79(1 Suppl):S215-55. DOI: 10.1152/physrev.1999.79.1.S215. View

Schneider E, Reyes-Ortega F, Li J, Velkov T . Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?. Clin Pharmacol Ther. 2016; 101(1):130-141. PMC: 5191968. DOI: 10.1002/cpt.548. View

10.

Younger J, Ren H, Chen L, Fan C, Fields A, Patterson C . A foldable CFTR{Delta}F508 biogenic intermediate accumulates upon inhibition of the Hsc70-CHIP E3 ubiquitin ligase. J Cell Biol. 2004; 167(6):1075-85. PMC: 2172621. DOI: 10.1083/jcb.200410065. View

11.

Harrington M, Gunderson K, Kopito R . Redox reagents and divalent cations alter the kinetics of cystic fibrosis transmembrane conductance regulator channel gating. J Biol Chem. 1999; 274(39):27536-44. DOI: 10.1074/jbc.274.39.27536. View

12.

Vij N, Fang S, Zeitlin P . Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. J Biol Chem. 2006; 281(25):17369-17378. DOI: 10.1074/jbc.M600509200. View

13.

Lukacs G, Chang X, Bear C, Kartner N, Mohamed A, Riordan J . The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. J Biol Chem. 1993; 268(29):21592-8. View

14.

Wang X, Matteson J, An Y, Moyer B, Yoo J, Bannykh S . COPII-dependent export of cystic fibrosis transmembrane conductance regulator from the ER uses a di-acidic exit code. J Cell Biol. 2004; 167(1):65-74. PMC: 2172508. DOI: 10.1083/jcb.200401035. View

15.

Cheng J, Cebotaru V, Cebotaru L, Guggino W . Syntaxin 6 and CAL mediate the degradation of the cystic fibrosis transmembrane conductance regulator. Mol Biol Cell. 2010; 21(7):1178-87. PMC: 2847522. DOI: 10.1091/mbc.e09-03-0229. View

16.

Loureiro C, Matos A, Dias-Alves A, Pereira J, Uliyakina I, Barros P . A molecular switch in the scaffold NHERF1 enables misfolded CFTR to evade the peripheral quality control checkpoint. Sci Signal. 2015; 8(377):ra48. DOI: 10.1126/scisignal.aaa1580. View

17.

Koulov A, LaPointe P, Lu B, Razvi A, Coppinger J, Dong M . Biological and structural basis for Aha1 regulation of Hsp90 ATPase activity in maintaining proteostasis in the human disease cystic fibrosis. Mol Biol Cell. 2010; 21(6):871-84. PMC: 2836968. DOI: 10.1091/mbc.e09-12-1017. View

18.

Wang X, Venable J, LaPointe P, Hutt D, Koulov A, Coppinger J . Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell. 2006; 127(4):803-15. DOI: 10.1016/j.cell.2006.09.043. View

19.

Sosnay P, Siklosi K, Van Goor F, Kaniecki K, Yu H, Sharma N . Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet. 2013; 45(10):1160-7. PMC: 3874936. DOI: 10.1038/ng.2745. View

20.

Lee H, Cheng J, Kovbasnjuk O, Donowitz M, Guggino W . Insulin-like growth factor 1 (IGF-1) enhances the protein expression of CFTR. PLoS One. 2013; 8(3):e59992. PMC: 3610909. DOI: 10.1371/journal.pone.0059992. View